Last reviewed · How we verify
Karbinal Er (CARBINOXAMINE)
Karbinal Er works by blocking the histamine H1 receptor, a key player in the body's allergic response.
Karbinal Er (Carbinoxamine) is a small molecule histamine-1 receptor antagonist developed by McNeil, currently owned by the same company. It was FDA-approved in 1974 for various allergic conditions, including allergic conjunctivitis, rhinitis, and urticaria. As an off-patent medication, it is available from multiple generic manufacturers. Key safety considerations include potential drowsiness and interactions with other medications. Commercially, it is available as a generic product.
At a glance
| Generic name | CARBINOXAMINE |
|---|---|
| Sponsor | Mcneil |
| Drug class | Histamine-1 Receptor Antagonist |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1974 |
Mechanism of action
Mechanismof Actions. Carbinoxamine maleate,an ethanolamine derivative, is an antihistamine with anticholinergic(drying) and sedative properties. Carbinoxamine appears to competewith histamine (type 1) for receptor siteson effector cells in the gastrointestinal tract, blood vessels andrespiratory tract.
Approved indications
- Allergic conjunctivitis
- Allergic rhinitis
- Common cold
- Dermatographic urticaria
- Itching of skin
- Nasal discharge
- Seasonal allergic rhinitis
- Urticaria
- Vasomotor rhinitis
Common side effects
- Urticaria
- Drug rash
- Anaphylactic shock
- Photosensitivity
- Hypotension
- Hemolytic anemia
- Thrombocytopenia
- Agranulocytosis
- Sedation
- Sleepiness
- Dizziness
- Disturbed coordination
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |